Lipella Pharmaceuticals (LIPO) announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus. The Phase 2a trial has now fully enrolled participants across all three dose cohorts at seven U.S. study sites. Topline results from the final cohort remain on track for the second quarter of 2025 and will represent the most comprehensive clinical dataset to date for LP-310.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals files to sell 5.62M shares of common stock for holders
- 3 Penny Stocks to Watch Now, 2/13/25
- Lipella Pharmaceuticals Gains Buy Rating from Jason McCarthy Following Positive Phase 2a Results for LP-310
- Lipella Pharmaceuticals Gains FDA Approval for LP-310
- Morning Movers: Lattice Semiconductor, SelectQuote jump after earnings reports